Evidence map›Paper›PMID 25632159›Full record

ArticleJournal of cell science2015

SOX9 inhibits β-TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties.

Wentao Deng, Daniel B Vanderbilt, Chen-Chung Lin, Karen H Martin, Kathleen M Brundage, J Michael Ruppert

Open access · greenAbstract read
In one paragraph

Article in Journal of cell science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. SKP1-CUL1-F-box: Key molecular targets affecting disease progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Observational
  15. GLI3: a mediator of genetic diseases, development and cancer.Cell communication and signaling : CCS · 2020
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wentao DengThe Department of Biochemistry, West Virginia University, Morgantown, West Virginia 26506 The Mary Babb Randolph Cancer Center, West Virginia University, West Virginia 26506.
Daniel B VanderbiltProgram in Cancer Cell Biology, West Virginia University, Morgantown, West Virginia 26506.
Chen-Chung LinThe Department of Biochemistry, West Virginia University, Morgantown, West Virginia 26506 The Mary Babb Randolph Cancer Center, West Virginia University, West Virginia 26506.
Karen H MartinThe Mary Babb Randolph Cancer Center, West Virginia University, West Virginia 26506.
Kathleen M BrundageThe Mary Babb Randolph Cancer Center, West Virginia University, West Virginia 26506.
J Michael RuppertThe Department of Biochemistry, West Virginia University, Morgantown, West Virginia 26506 The Mary Babb Randolph Cancer Center, West Virginia University, West Virginia 26506 Program in Cancer Cell Biology, West Virginia University, Morgantown, West Virginia 26506 mruppert@hsc.wvu.edu.
West Virginia University · US

Funding

WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI GARY O RANKIN · 2012 to 2026
$61.1M
WVU &MU NEW FACULTY GRANTSP20RR016477 · NCRR · MARSHALL UNIVERSITY · PI RANKIN, GARY O · 2001 to 2011
$35.5M
THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8M
Klf4 in tumor initiation and maintenance of squamous cell carcinomaR01CA127405 · NCI · WEST VIRGINIA UNIVERSITY · PI RUPPERT, JOHN MICHAEL · 2007 to 2011
$1.4M
COBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE IIIP30RR032138 · NCRR · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2011 to 2011
$1.1M
BECTON-DICKINSON FACSARIA FLOW CYTOMETER: SARCOPENIAS10RR020866 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2006 to 2006
$425k
NCI NIH HHS R01 CA127405NCRR NIH HHS P20 RR016440NCRR NIH HHS P20 RR016477NCRR NIH HHS P30 RR032138NCRR NIH HHS RR020866NCRR NIH HHS S10 RR020866NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P20GM103434NIGMS NIH HHS P30 GM103488NIGMS NIH HHS P30GM103488NIGMS NIH HHS P30 RR032138/GM103488
6 · The paper itself

Abstract

The high mobility group box protein SOX9 and the GLI1 transcription factor play protumorigenic roles in pancreatic ductal adenocarcinoma (PDA). In Kras transgenic mice, each of these factors are crucial for the development of PDA precursor lesions. SOX9 transcription is directly regulated by GLI1, but how SOX9 functions downstream of GLI1 is unclear. We observed positive feedback, such that SOX9-deficient PDA cells have severely repressed levels of endogenous GLI1, attributed to loss of GLI1 protein stability. SOX9 associated with the F-box domain of the SKP1/CUL1/F-box (SCF) E3 ubiquitin ligase component, β-TrCP (also known as F-box/WD repeat-containing protein 1A), and suppressed its association with SKP1 and GLI1, a substrate of SCF-β-TrCP. SOX9 also tethered β-TrCP within the nucleus and promoted its degradation. SOX9 bound to β-TrCP through the SOX9 C-terminal PQA/S domain that mediates transcriptional activation. Suppression of β-TrCP in SOX9-deficient PDA cells restored GLI1 levels and promoted SOX9-dependent cancer stem cell properties. These studies identify SOX9-GLI1 positive feedback as a major determinant of GLI1 protein stability and implicate β-TrCP as a latent SOX9-bound tumor suppressor with the potential to degrade oncogenic proteins in tumor cells.

Indexed as

AdenocarcinomaAnimalsAnoikisApoptosisbeta-Transducin Repeat-Containing ProteinsBlotting, WesternCarcinoma, Pancreatic DuctalCell NucleusCell ProliferationCells, CulturedFlow CytometryFluorescent Antibody TechniqueHumansMiceNeoplastic Stem CellsOncogene Proteinsbeta-Transducin Repeat-Containing ProteinsOncogene ProteinsRNA, MessengerSOX9 Transcription FactorTrans-ActivatorsZinc Finger Protein GLI1GLI1Pancreatic ductal adenocarcinomaSOX9β-TrCP

Identifiers

PMID25632159
PMCPMC4359920
OpenAlexW1986083284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.